Kodak share soars post active drug ingredient development deal
Author : Saipriya Iyer | Published Date : 2020-07-30
Shares of Eastman Kodak, an American technology company, have recently increased, following the announcement of a deal by the U.S. President Donald Trump. The agreement is regarding the President’s collaboration with the company to produce active ingredients for generic medicines to fight against the deadly COVID-19 disease.
In the extended trading, the shares of Kodak have soared by more than 318%, to nearly $25.26 per share. The U.S. government has offered a $765 million loan to the company to commence the production of ingredients for the generic drugs, under the Defense Production Act.
The U.S. president has reportedly stated that the country’s 33rd adoption of the Defense Production Act will mobilize Kodak in manufacturing active pharmaceutical ingredients. This will also aid America in becoming the premier medical supplier and manufacturer.
The photography company has cited that it will provide essential pharmaceutical components to meet the chronic shortages in the nation, as defined by the U.S. FDA. The recent 1,300% increase in the stock price has recently enabled it to record a market capitalization of over $1.5 billion. Prior to this, the company registered a value of nearly $115 million.
To ensure rapid production, Kodak will expand its existing facilities in St. Paul, Minnesota, New York, and Rochester, under a new arm of Kodak Pharmaceuticals.
As per the statement made by Jim Continenza, Executive Chairman of Kodak, the company is excited to play a key role in strengthening the country’s self-sufficiency by offering major ingredients in the U.S. It will leverage its heritage in quality and innovation, deep expertise in chemicals production, and vast infrastructure to advance America as a reliable pharmaceutical supply chain.
In 2012, the company had filed for bankruptcy due to the shifting consumer preferences to digital cameras. The recent deal to enter the drug production business will present a significant growth opportunity for the company.
Source credit:
https://www.cnbc.com/2020/07/28/kodak-soars-another-40percent-after-trump-announces-deal-to-manufacture-generic-drug-ingredients.html
About Author
Saipriya Iyer . .
Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i
Related News
Hero MotoCorp under investigation by Ministry of Corporate Affairs
The Indian Ministry of Corporate Affairs has reportedly ordered a probe into Hero MotoCorp to examine its association with an external vendor regarding alleged fund diversion. The objective of the investigation, conducted in the "public interest," is to evaluate the Hero MotoCorp owners... Read More>>
UK: Residents receive bills of up to £49,000 after Ovo acquires SSE
Customers of Ovo, the energy supplier were reportedly left shocked when they received energy bills of up to £49,000, due to data errors that led to overinflated energy bills for some residents. Ovo accepted that some of its customers have been affected by erroneous meter readings, and it bl... Read More>>
Bob Iger returns to Disney as CEO less than a year post retirement
Bob Iger, the ex-CEO of Walt Disney Co., is reportedly coming back to the mass media giant less than a year after his retirement. The surprise announcement comes at a time when Disney is struggling to earn profits from its streaming TV services. According to a statement released by Disney late Su... Read More>>